A Phase 2 interventional study of Hydroxychloroquine sulfate and Placebo in Interstitial Lung Disease, Diffuse Parenchymal Lung Disease and Children´s Interstitial Lung Disease, sponsored by Matthias Griese. Terminated at 9 sites in Germany. Open to participants aged 3 Weeks to 99 Years. Per ClinicalTrials.gov, last updated 2025-12-03.
Sponsored by Matthias Griese · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies in Lung Diseases, Interstitial with a site in Germany — 18 open to participants now, 26 under way, 13 of them phase 3. Lung Diseases, Interstitial · Germany.
Among the 66 studies in Lung Diseases, Interstitial with a site in Germany, this one is the 43rd largest by enrollment of the 51 interventional ones that give a count, is one of 4 that started in 2015, is one of 15 in phase 2, and was the 17th registered.
682 studies on the registry are indexed under Lung Diseases, Interstitial; 245 are open to participants now.
Browse Lung Diseases, Interstitial studies →18 of the 66 studies in Lung Diseases, Interstitial with a site in Germany are open now. Recruiting first, the newest first:
Boehringer Ingelheim · Sites in Germany, United States, Argentina and 17 more countries
Ages 18+
Boehringer Ingelheim · Sites in Germany, United States, Argentina and 19 more countries
Ages 2–17
Insmed Incorporated · Sites in Germany, United States, Czechia and 5 more countries
Ages 18+
Liquidia Technologies, Inc. · Sites in Germany, United States, Australia and 9 more countries
Ages 18–80
Boehringer Ingelheim · Sites in Germany, United States, Argentina and 10 more countries
Ages 40+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 172 Lung Diseases, Interstitial studies recruiting now, 108 (63%) set no upper age limit and 25 (15%) stop at 75 or younger; 13 take children under 18; 21 take healthy volunteers.
This study: 3 Weeks to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 18 · Phase 3 24
First in 2003; this study’s year is marked. 4 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 35 is below the median of 60 across 386 interventional studies indexed under Lung Diseases, Interstitial.
Median enrollment 183 across the 51 interventional studies, 500 across the 15 observational. Of the 32 that completed or were terminated, 15 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 66 have an industry lead sponsor. The 10 most frequent:
Matthias Griese is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Matthias Griese has 2 studies filed under Lung Diseases, Interstitial — fewer than ten, so there is no comparison to draw.
7 of the studies in Lung Diseases, Interstitial with a site in Germany that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05925803Phase 3AstraZenecaDetermine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) | 2027-01-06 |
| NCT06806592Phase 3Boehringer IngelheimA Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases | 2027-04-15 |
| NCT05943535Phase 3United TherapeuticsStudy of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) | 2027-11 |
| NCT07300696University Hospital HeidelbergFunctional MRI for Monitoring Progression and Assessing Trends in ILD | 2027-02 |
| NCT07175038AllRock Bio, Inc.A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY) | 2027-03 |
Add all 7 to your calendar (.ics) → With an account.
Among the 66 studies in Lung Diseases, Interstitial with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an exploratory Phase 2, randomized, double-blind, placebo-controlled, parallel-group, multinational study investigating the initiation or withdrawal of hydroxychloroquine in subjects with chILD.
This study is an explorative, prospective, randomized, double-blind, placebo controlled investigation of hydroxychloroquine (HCQ) in pediatric ILD. The treatments are organized in START and STOP blocks, which can be initiated in sequence, as needed by the subjects. Each patient can participate in each block only once. In the START block subjects are randomized to parallel-groups, then the placebo group is switched to active drug. In the STOP block, subjects on HCQ are randomized into parallel-groups treated with placebo or HCQ to investigate the withdrawal of HCQ for assessment of its efficacy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients should be clinically stable during baseline (between Visit 1 and 2) for inclusion into the study
Diagnosis of chronic (≥ 3 wks of duration) diffuse parenchymal lung disease (DPLD = chILD), defined in at least one of the following ways:
chILD diagnosed
(*may be diagnosed in the absence of a lung by characteristic lung lavage cytology (PAS stain, Fe stain), CT pattern or autoantibodies (gliadin, endomysium; cANCA) and clinical course.)
Exclusion criteria:
Subjects presenting with any of the following criteria will not be included in the trial:
Renal insufficiency at screening, defined as (GFR)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
4 weeks of Hydroxychloroquine Sulfate (HCQ, Quensyl) in a loading dose of 10 mg/kg bw/d, p.o., once daily dose in the evening for 7 days, then reduction to 6.5 mg/kg bw/d for 3 weeks; the maximum daily dose is 400 mg. Then 4 weeks Hydroxychloroquine Sulfate (HCQ, Quensyl). First week loading dose 10 mg/kg bw/d, p.o., once daily in the evening, followed by 6.5 mg/kg bw/d for 3 weeks.
Drug: Hydroxychloroquine sulfate
4 weeks of Placebo in a loading dose of 10 mg/kg bw/d, p.o., one daily dose in the evening for 7 days, then reduction to 6.5 mg/kg bw/d for 3 weeks; the maximum daily dose is 400 mg. Then 4 weeks Hydroxychloroquine Sulfate (HCQ, Quensyl). First week loading dose 10 mg/kg bw/d, p.o., once daily in the evening, followed by 6.5 mg/kg bw/d for 3 weeks.
Other: Placebo
Individual dose of Hydroxychloroquine Sulfate (HCQ, Quensyl) 6-10 mg/kg bw/d, p.o., once daily in the evening; the maximum daily dose is 400 mg. The dose on which the patient was included into the trial was continued for 3 months. Then the medication was stopped and the patient followed for additional 3 months.
Drug: Hydroxychloroquine sulfate
Individual dose of Placebo 6-10 mg/kg bw/d, p.o., once daily in the evening; the maximum daily dose is 400 mg. The dose on which the patient was included into the trial was continued for 3 months. Then the medication was stopped and the patient wo received HCQ will be followed up for additional 3 months with no medication.
Other: Placebo
Apply drug to modify lysosomal pH
Also known as: Quensyl
Apply Placebo not to modify lysosomal pH
Also known as: no other name
Change in Oxygenation (Presence or Absence of Response to Treatment) Defined as Change in O2 Saturation >=5%, or Change in Respiratory Rate >=20%, or Change in Respiratory Support Necessary
O2 saturation measured after 5 min at rest and after withdrawal of oxygen if supplied. Change in Oxygenation (presence or absence of response to treatment) defined as change in O2 saturation \>=5%, or change in respiratory rate \>=20%, or change in respiratory support necessary
Time frame: Start block: A,B after 4 and C,D after 8 weeks; Stop block: E,F after 12 and G,H after 24 weeks
Change in Oxygenation (Presence or Absence of Response to Treatment) Defined as Change in O2 Saturation >=3%, or Change in Respiratory Rate >=20%, or Change in Respiratory Support Necessary
O2 saturation measured after 5 min at rest and after withdrawal of oxygen if supplied. Change in Oxygenation (presence or absence of response to treatment) defined as change in O2 saturation \>=3%, or change in respiratory rate \>=20%, or change in respiratory support necessary
Time frame: Start block: A,B after 4 and C,D after 8 weeks; Stop block: E,F after 12 and G,H after 24 weeks
Change of O2-sat in Room Air (%)
Oxygen saturation in room air at rest
Time frame: Start block: A,B after 4 and C,D after 8 weeks; Stop block: E,F after 12 and G,H after 24 weeks
Change of Respiratory Rate in Room Air (Breaths/Min)
Respiratory rate in room air at rest measured in breaths per minute
Time frame: Start block: A,B after 4 and C,D after 8 weeks; Stop block: E,F after 12 and G,H after 24 weeks
Change of Quality of Life (chILD Specific)
Quality of life (chILD specific) questionaire. A 5-point response scale was utilized (0 = never a problem; 1=almost never a problem; 2=sometimes a problem; 3=often a problem; 4=almost always a problem). Items were reverse-scored and linearly transformed to a 0-100 scale (0 = 100, 1 = 75, 2 = 50, 3 = 25, 4 = 0). Higher scores indicate better HrQoL.
Time frame: Start block: A,B after 4 and C,D after 8 weeks; Stop block: E,F after 12 and G,H after 24 weeks
Change of Quality of Life (Total Score)
Quality of life (total score) questionaire. A 5-point response scale was utilized (0 = never a problem; 1=almost never a problem; 2=sometimes a problem; 3=often a problem; 4=almost always a problem). Items were reverse-scored and linearly transformed to a 0-100 scale (0 = 100, 1 = 75, 2 = 50, 3 = 25, 4 = 0). Higher scores indicate better HrQoL.
Time frame: Start block: A,B after 4 and C,D after 8 weeks; Stop block: E,F after 12 and G,H after 24 weeks
Change of BMI Percentile
BMI percentile to adapt for age and sex related differences
Time frame: Start block: A,B after 4 and C,D after 8 weeks; Stop block: E,F after 12 and G,H after 24 weeks
Change of LDH (U/ml)
Lactate dehydrogenase
Time frame: Start block: A,B after 4 and C,D after 8 weeks; Stop block: E,F after 12 and G,H after 24 weeks
Absolute Change of Forced Vital Capacity (FVC) (% Predicted of the Reference Population)
FVC predicted expressed in % of the normal reference population (Quanjer PH, Brazzale DJ, Boros PW, et al. Implications of adopting the Global Lungs Initiative 2012 all-age reference equations for spirometry. Eur Respir J. 2013;42:1046-54.) The absolute change in FVC % predicited between two measurements is reported.
Time frame: Start block: A,B after 4 and C,D after 8 weeks; Stop block: E,F after 12 and G,H after 24 weeks
Absolute Change of Forced Expiratory Volume in One Second (FEV1) (% Predicted of the Reference Population)
FEV1 predicted expressed in % of the normal reference population (Quanjer PH, Brazzale DJ, Boros PW, et al. Implications of adopting the Global Lungs Initiative 2012 all-age reference equations for spirometry. Eur Respir J. 2013;42:1046-54.). The absolute change in FEV1 % predicited between two measurements is reported.
Time frame: Start block: A,B after 4 and C,D after 8 weeks; Stop block: E,F after 12 and G,H after 24 weeks
Absolute Change of Mean Expiratory Flow Between 25 and 75% of Vital Capacity (MEF25-75) (% Predicted of the Reference Population)
MEF25-75 predicted expressed in % of the normal reference population (Quanjer PH, Brazzale DJ, Boros PW, et al. Implications of adopting the Global Lungs Initiative 2012 all-age reference equations for spirometry. Eur Respir J. 2013;42:1046-54.). The absolute change in MEF25-75 % predicited between two measurements is reported.
Time frame: Start block: A,B after 4 and C,D after 8 weeks; Stop block: E,F after 12 and G,H after 24 weeks
Absolute Change of Six Minute Walking Test (6MWT) Distance (% Predicted of the Reference Population)
6 Minute walking distance expressed as % of the predicted distance for age and sex. Ulrich et al, Reference values for the 6-minute walk test. BMC Pulm Med. 2013 Aug 5:13:49. doi: 10.1186/1471-2466-13-49. The absolute difference of two measuremnts between two time points is reported.
Time frame: Start block: A,B after 4 and C,D after 8 weeks; Stop block: E,F after 12 and G,H after 24 weeks
| Milestone | Start Placebo, Then HCQ | Start HCQ, Then HCQ | Stop HCQ, Then no Medication | Stop Placebo, Then no Medication |
|---|---|---|---|---|
| Started | 17 | 9 | 4 | 5 |
| Completed | 13 | 7 | 3 | 5 |
| Not completed | 4 | 2 | 1 | 0 |
| Withdrew: Physician decision | 3 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 |
| Milestone | Start Placebo, Then HCQ | Start HCQ, Then HCQ | Stop HCQ, Then no Medication | Stop Placebo, Then no Medication |
|---|---|---|---|---|
| Started | 13 | 7 | 3 | 5 |
| Completed | 12 | 7 | 3 | 5 |
| Not completed | 1 | 0 | 0 | 0 |
O2 saturation measured after 5 min at rest and after withdrawal of oxygen if supplied. Change in Oxygenation (presence or absence of response to treatment) defined as change in O2 saturation \>=5%, or change in respiratory rate \>=20%, or change in respiratory support necessary
| Participants | Start Placebo, Then HCQ (Group A) | Start HCQ, Then HCQ (Group B) | Start Placebo, Then HCQ (Group C) | Start HCQ, Then HCQ (Group D) | Stop HCQ, Then no Medication (Group E) | Stop Placebo, Then no Medication (Group F) | Stop HCQ, Then no Medication (Group G) | Stop Placebo, Then no Medication (Group H) |
|---|---|---|---|---|---|---|---|---|
| Responder | 0 | 0 | 3 | 0 | 0 | 0 | 1 | 1 |
| Non-responder | 13 | 7 | 9 | 7 | 3 | 5 | 2 | 4 |
O2 saturation measured after 5 min at rest and after withdrawal of oxygen if supplied. Change in Oxygenation (presence or absence of response to treatment) defined as change in O2 saturation \>=3%, or change in respiratory rate \>=20%, or change in respiratory support necessary
| Participants | Start Placebo, Then HCQ (Group A) | Start HCQ, Then HCQ (Group B) | Start Placebo, Then HCQ (Group C) | Start HCQ, Then HCQ (Group D) | Stop HCQ, Then no Medication (Group E) | Stop Placebo, Then no Medication (Group F) | Stop HCQ, Then no Medication (Group G) | Stop Placebo, Then no Medication (Group H) |
|---|---|---|---|---|---|---|---|---|
| Responder | 2 | 1 | 2 | 0 | 0 | 3 | 1 | 1 |
| Non-responder | 11 | 5 | 10 | 6 | 3 | 2 | 2 | 4 |
Oxygen saturation in room air at rest
| percentage of O2 Sat | Start Placebo, Then HCQ (Group A) | Start HCQ, Then HCQ (Group B) | Start Placebo, Then HCQ (Group C) | Start HCQ, Then HCQ (Group D) | Stop HCQ, Then no Medication (Group E) | Stop Placebo, Then no Medication (Group F) | Stop HCQ, Then no Medication (Group G) | Stop Placebo, Then no Medication (Group H) |
|---|---|---|---|---|---|---|---|---|
| Change of O2-sat in Room Air (%) | -0.1 ± 2.4 | -0.6 ± 3.3 | 1.8 ± 3.5 | -1.7 ± 2.6 | 0.3 ± 1.2 | -2.4 ± 2.7 | -3.7 ± 6.4 | 0.2 ± 4.8 |
Respiratory rate in room air at rest measured in breaths per minute
| breaths/min | Start Placebo, Then HCQ (Group A) | Start HCQ, Then HCQ (Group B) | Start Placebo, Then HCQ (Group C) | Start HCQ, Then HCQ (Group D) | Stop HCQ, Then no Medication (Group E) | Stop Placebo, Then no Medication (Group F) | Stop HCQ, Then no Medication (Group G) | Stop Placebo, Then no Medication (Group H) |
|---|---|---|---|---|---|---|---|---|
| Change of Respiratory Rate in Room Air (Breaths/Min) | 1.2 ± 5.4 | 0.2 ± 0.4 | -1.3 ± 5.6 | 13.8 ± 33.1 | -2.7 ± 1.2 | -5.4 ± 9.4 | 7.3 ± 5 | 2.5 ± 7.9 |
Quality of life (chILD specific) questionaire. A 5-point response scale was utilized (0 = never a problem; 1=almost never a problem; 2=sometimes a problem; 3=often a problem; 4=almost always a problem). Items were reverse-scored and linearly transformed to a 0-100 scale (0 = 100, 1 = 75, 2 = 50, 3 = 25, 4 = 0). Higher scores indicate better HrQoL.
| score on a scale | Start Placebo, Then HCQ (Group A) | Start HCQ, Then HCQ (Group B) | Start Placebo, Then HCQ (Group C) | Start HCQ, Then HCQ (Group D) | Stop HCQ, Then no Medication (Group E) | Stop Placebo, Then no Medication (Group F) | Stop HCQ, Then no Medication (Group G) | Stop Placebo, Then no Medication (Group H) |
|---|---|---|---|---|---|---|---|---|
| Change of Quality of Life (chILD Specific) | 6.9 ± 9.6 | 0.1 ± 3.18 | -3.2 ± 4.8 | -9.1 ± 3.25 | -5.7 ± 11.2 | 7.5 ± 2.3 | 2.3 ± 3.2 | -2.0 ± 12.3 |
Quality of life (total score) questionaire. A 5-point response scale was utilized (0 = never a problem; 1=almost never a problem; 2=sometimes a problem; 3=often a problem; 4=almost always a problem). Items were reverse-scored and linearly transformed to a 0-100 scale (0 = 100, 1 = 75, 2 = 50, 3 = 25, 4 = 0). Higher scores indicate better HrQoL.
| score on a scale | Start Placebo, Then HCQ (Group A) | Start HCQ, Then HCQ (Group B) | Start Placebo, Then HCQ (Group C) | Start HCQ, Then HCQ (Group D) | Stop HCQ, Then no Medication (Group E) | Stop Placebo, Then no Medication (Group F) | Stop HCQ, Then no Medication (Group G) | Stop Placebo, Then no Medication (Group H) |
|---|---|---|---|---|---|---|---|---|
| Change of Quality of Life (Total Score) | 0.4 ± 6.9 | 0.3 ± 1.2 | 4.8 ± 4.3 | 0.4 ± 7.0 | 9.2 ± 5.4 | -9.5 ± 8.8 | -1.7 ± 2.3 | -5.5 ± 4.3 |
BMI percentile to adapt for age and sex related differences
| percentile | Start Placebo, Then HCQ (Group A) | Start HCQ, Then HCQ (Group B) | Start Placebo, Then HCQ (Group C) | Start HCQ, Then HCQ (Group D) | Stop HCQ, Then no Medication (Group E) | Stop Placebo, Then no Medication (Group F) | Stop HCQ, Then no Medication (Group G) | Stop Placebo, Then no Medication (Group H) |
|---|---|---|---|---|---|---|---|---|
| Change of BMI Percentile | 7.5 ± 11.7 | -1.8 ± 5.1 | -1.6 ± 8.1 | 22.6 ± 43.7 | -3.3 ± 7.9 | 2.2 ± 11.4 | 13.3 ± 20.9 | 3.9 ± 9.2 |
Lactate dehydrogenase
| Enzyme activity units per ml | Start Placebo, Then HCQ (Group A) | Start HCQ, Then HCQ (Group B) | Start Placebo, Then HCQ (Group C) | Start HCQ, Then HCQ (Group D) | Stop HCQ, Then no Medication (Group E) | Stop Placebo, Then no Medication (Group F) | Stop HCQ, Then no Medication (Group G) | Stop Placebo, Then no Medication (Group H) |
|---|---|---|---|---|---|---|---|---|
| Change of LDH (U/ml) | -28.2 ± 53.7 | 43.0 ± 61 | 11.3 ± 67 | -32.2 ± 55.3 | 34.5 ± 0.7 | 9.3 ± 65.5 | — | — |
FVC predicted expressed in % of the normal reference population (Quanjer PH, Brazzale DJ, Boros PW, et al. Implications of adopting the Global Lungs Initiative 2012 all-age reference equations for spirometry. Eur Respir J. 2013;42:1046-54.) The absolute change in FVC % predicited between two measurements is reported.
| percentage of reference population | Start Placebo, Then HCQ (Group A) | Start HCQ, Then HCQ (Group B) | Start Placebo, Then HCQ (Group C) | Start HCQ, Then HCQ (Group D) | Stop HCQ, Then no Medication (Group E) | Stop Placebo, Then no Medication (Group F) | Stop HCQ, Then no Medication (Group G) | Stop Placebo, Then no Medication (Group H) |
|---|---|---|---|---|---|---|---|---|
| Absolute Change of Forced Vital Capacity (FVC) (% Predicted of the Reference Population) | 0.0 ± 3.7 | 2.5 ± 13 | 10.6 ± 19.7 | -1.0 ± 4.2 | 2.3 ± 7.6 | 0.5 ± 2.1 | -1.3 ± 5.1 | 4.5 ± 4.9 |
FEV1 predicted expressed in % of the normal reference population (Quanjer PH, Brazzale DJ, Boros PW, et al. Implications of adopting the Global Lungs Initiative 2012 all-age reference equations for spirometry. Eur Respir J. 2013;42:1046-54.). The absolute change in FEV1 % predicited between two measurements is reported.
| percentage of reference population | Start Placebo, Then HCQ (Group A) | Start HCQ, Then HCQ (Group B) | Start Placebo, Then HCQ (Group C) | Start HCQ, Then HCQ (Group D) | Stop HCQ, Then no Medication (Group E) | Stop Placebo, Then no Medication (Group F) | Stop HCQ, Then no Medication (Group G) | Stop Placebo, Then no Medication (Group H) |
|---|---|---|---|---|---|---|---|---|
| Absolute Change of Forced Expiratory Volume in One Second (FEV1) (% Predicted of the Reference Population) | 0.6 ± 4.1 | 2.0 ± 13.1 | 9.0 ± 18.6 | 0.5 ± 5.1 | 0.0 ± 4.4 | -0.5 ± 0.7 | -1.0 ± 4.4 | 5.5 ± 4.9 |
MEF25-75 predicted expressed in % of the normal reference population (Quanjer PH, Brazzale DJ, Boros PW, et al. Implications of adopting the Global Lungs Initiative 2012 all-age reference equations for spirometry. Eur Respir J. 2013;42:1046-54.). The absolute change in MEF25-75 % predicited between two measurements is reported.
| percentage of reference population | Start Placebo, Then HCQ (Group A) | Start HCQ, Then HCQ (Group B) | Start Placebo, Then HCQ (Group C) | Start HCQ, Then HCQ (Group D) | Stop HCQ, Then no Medication (Group E) | Stop Placebo, Then no Medication (Group F) | Stop HCQ, Then no Medication (Group G) | Stop Placebo, Then no Medication (Group H) |
|---|---|---|---|---|---|---|---|---|
| Absolute Change of Mean Expiratory Flow Between 25 and 75% of Vital Capacity (MEF25-75) (% Predicted of the Reference Population) | 3.0 ± 13.1 | -14.8 ± 15.2 | -2.6 ± 8.6 | 18.5 ± 17.4 | -8.7 ± 14.2 | -7.0 ± 1.4 | -11.3 ± 7.8 | 15.5 ± 6.4 |
6 Minute walking distance expressed as % of the predicted distance for age and sex. Ulrich et al, Reference values for the 6-minute walk test. BMC Pulm Med. 2013 Aug 5:13:49. doi: 10.1186/1471-2466-13-49. The absolute difference of two measuremnts between two time points is reported.
| percentage of reference population | Start Placebo, Then HCQ (Group A) | Start HCQ, Then HCQ (Group B) | Start Placebo, Then HCQ (Group C) | Start HCQ, Then HCQ (Group D) | Stop HCQ, Then no Medication (Group E) | Stop Placebo, Then no Medication (Group F) | Stop HCQ, Then no Medication (Group G) | Stop Placebo, Then no Medication (Group H) |
|---|---|---|---|---|---|---|---|---|
| Absolute Change of Six Minute Walking Test (6MWT) Distance (% Predicted of the Reference Population) | -0.8 ± 3.6 | -31.0 ± NA | 0.8 ± 2.1 | 44 ± NA | 0.3 ± 8.5 | -0.5 ± 2.1 | 8.7 ± 12.6 | -3.0 ± 2.8 |
Collected over Adverse events were collected separately according their occurance during Start periods (8 weeks) or Stop periods (6 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Start Placebo, Then HCQ | 0/13 (0%) | 1/13 (7.7%) | 12/13 (92.3%) |
| Start HCQ, Then HCQ | 0/7 (0%) | 0/7 (0%) | 7/7 (100%) |
| Stop HCQ, Then no Medication | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| Stop Placebo, Then no Medication | 0/5 (0%) | 0/5 (0%) | 5/5 (100%) |
| Event | Start Placebo, Then HCQ | Start HCQ, Then HCQ | Stop HCQ, Then no Medication | Stop Placebo, Then no Medication |
|---|---|---|---|---|
| Placebogroup Startarm SAE due to infectionInfections and infestations | 1/13 | 0/7 | 0/4 | 0/5 |
| Event | Start Placebo, Then HCQ | Start HCQ, Then HCQ | Stop HCQ, Then no Medication | Stop Placebo, Then no Medication |
|---|---|---|---|---|
| InfectionsInfections and infestations | 9/13 | 3/7 | 2/4 | 4/5 |
| AEs gastrointestinal disorderInfections and infestations | 2/13 | 2/7 | 2/4 | 1/5 |
| AE respiratory disorderRespiratory, thoracic and mediastinal disorders | 2/13 | 1/7 | 2/4 | 1/5 |
| AE General disordersGeneral disorders | 1/13 | 1/7 | 0/4 | 1/5 |
| AE Musculoskeletal and connective tissueMusculoskeletal and connective tissue disorders | 1/13 | 0/7 | 0/4 | 1/5 |
| AE BloodBlood and lymphatic system disorders | 1/13 | 0/7 | 0/4 | 0/5 |
| AE psychiatric disordersPsychiatric disorders | 1/13 | 0/7 | 0/4 | 0/5 |
| AE Nervouse SystemNervous system disorders | 1/13 | 0/7 | 0/4 | 0/5 |
| AE Eye disordersEye disorders | 1/13 | 0/7 | 0/4 | 0/5 |
| Age, Customized(n amount of patients) | Start Placebo (Group A), Then Continue HCQ (Group C) | Start HCQ (Group B), Then Continue HCQ (Group D) | Stop HCQ (Group E), Then Continued no Medication (Group G) | Stop Placebo (Group F), Then Continued no Medication (Group H) | Total |
|---|---|---|---|---|---|
| Number | 9 | 7.8 | 8.2 | 9.2 | 0 |
| Sex: Female, Male(Participants) | Start Placebo (Group A), Then Continue HCQ (Group C) | Start HCQ (Group B), Then Continue HCQ (Group D) | Stop HCQ (Group E), Then Continued no Medication (Group G) | Stop Placebo (Group F), Then Continued no Medication (Group H) | Total |
|---|---|---|---|---|---|
| Female | 10 | 7 | 2 | 3 | 22 |
| Male | 7 | 2 | 2 | 2 | 13 |
| Race (NIH/OMB)(Participants) | Start Placebo (Group A), Then Continue HCQ (Group C) | Start HCQ (Group B), Then Continue HCQ (Group D) | Stop HCQ (Group E), Then Continued no Medication (Group G) | Stop Placebo (Group F), Then Continued no Medication (Group H) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 16 | 9 | 4 | 5 | 34 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Start Placebo (Group A), Then Continue HCQ (Group C) | Start HCQ (Group B), Then Continue HCQ (Group D) | Stop HCQ (Group E), Then Continued no Medication (Group G) | Stop Placebo (Group F), Then Continued no Medication (Group H) | Total |
|---|---|---|---|---|---|
| Germany | 17 | 9 | 4 | 5 | 35 |
| O2 sat [%](% 02 saturation) | Start Placebo (Group A), Then Continue HCQ (Group C) | Start HCQ (Group B), Then Continue HCQ (Group D) | Stop HCQ (Group E), Then Continued no Medication (Group G) | Stop Placebo (Group F), Then Continued no Medication (Group H) | Total |
|---|---|---|---|---|---|
| Number | 92.6 | 93.9 | 93.7 | 94.8 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2015 to primary completion in Jun 2019, 46 months.
Results were first posted in Dec 2025, 6 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Hydroxychloroquine